Calidi Biotherapeutics, Inc. CLDI
Calidi Biotherapeutics, Inc. (NYSE: CLDI) is an oncology drug developer. Its lead program, NeuroNova (stem-cell-based oncolytic virus), is in Phase 1 for oncology (investigator-initiated Phase 1 run by City of Hope). Its next catalyst on record is CLD-401: Enter the clinic (first-in-human) (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CLD-401 — Enter the clinic (first-in-human) (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| NeuroNova | oncology (investigator-initiated trial, City of Hope) | gene therapy | Phase 1 |
| SuperNova (CLD-201) | soft tissue sarcoma (Fast Track) | gene therapy | Pre-clinical |
| CLD-401 (RedTail, IL-15 superagonist) | metastatic solid tumors | gene therapy | Pre-clinical |
| CLD-501 (RedTail, anti-TROP2 TCE + IL-15) | solid tumors | gene therapy | Pre-clinical |
| CLD-502 (RedTail, anti-EpCAM TCE + IL-15) | solid tumors | gene therapy | Pre-clinical |
Recent results and decisions
- Sep 21, 2026n/a Calidi received NYSE American notice of non-compliance with stockholders' equity requirement, must submit compliance plan by October 21, 2026 and regain compliance by March 21, 2028.
The Company reported stockholders' equity of $3.1 million as of June 30, 2026, and net losses in three of its four most recent fiscal years ended December 31, 2025.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.